All In Biotech

Drug Trial Radar · NCT03406611

Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study)

A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Effects on Clinical Outcomes of Pegtibatinase (TVT-058) Administered Subcutaneously in Subjects With Cystathionine Beta Synthase-Deficient Homocystinuria (COMPOSE)

Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

39

Planned (sponsor's estimate)

Start

Jan 22, 2019

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Travere Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jan 23, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for a better way to treat people who have classical homocystinuria (HCU), a rare condition that is passed down by parents (or "genetic condition"). It is caused by changes in the cystathionine beta-synthase (or "CBS") gene and prevents an enzyme from working correctly in the body. This enzyme breaks down a substance called homocysteine (from dietary methionine found in protein) and keeps both homocysteine and methionine at normal levels. When this enzyme is not working, homocysteine and methionine build up in the blood, which spreads into different tissues of the body and stops these body tissues from working normally. People with HCU can experience problems with vision, bones, blood vessels, and cognitive function (the ability to think, learn, and remember). Treatments available for HCU, such as a low protein diet and betaine (Cystadane®), help reduce homocysteine levels. The diet is a low methionine diet and a methionine-free protein supplement (a product that provides extra protein to help meet daily protein needs). These treatments are either not sufficient or are hard to take for many patients. Pegtibatinase was developed by scientists to be a version of the CBS enzyme that can be given to people with HCU. Researchers believe that giving pegtibatinase to people with HCU already getting medical treatment (or "standard of care") may reduce their homocysteine levels. This study is split into 7 different groups getting different amounts of drug. The first 6 groups have already finished the study. Group 7 plans to enroll participants from the US (virtual and in-person), France, and Qatar.

Conditions

  • Homocystinuria

Interventions

  • PegtibatinaseDrug

    Pegtibatinase sterile solution for subcutaneous injection

  • PlaceboDrug

    Normal saline for subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of AEsTime frame: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
  2. Anti-pegtibatinase antibodiesTime frame: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
  3. Anti-PEG antibodiesTime frame: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
  4. Incidence of hypermethioninemia (Cohort 7 only)Time frame: First dose through End of Treatment (up to Week 32)
  5. Incidence of hypomethioninemia (Cohort 7 only)Time frame: First dose through End of Treatment (up to Week 32)
  6. The proportion of participants requiring dietary protein rescue (Cohort 7 only)Time frame: First dose through End of Treatment (up to Week 32)

Locations

12 sites in 3 countries. Site status is shown where the registry gives one.

  • Travere Investigational Site

    Aurora, Colorado · Completed

  • Travere Investigational Site

    Miami, Florida · Completed

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois · Not yet recruiting

  • Travere Investigational Site

    Indianapolis, Indiana · Completed

  • Travere Investigational Site

    Portland, Maine · Completed

  • Travere Investigational Site

    Boston, Massachusetts · Completed

  • The Mount Sinai Hospital

    New York, New York · Not yet recruiting

  • Travere Investigational Site

    New York, New York · Completed

  • Science 37 - Virtual Site

    Morrisville, North Carolina · Recruiting

  • Travere Investigational Site

    Philadelphia, Pennsylvania · Completed

  • Hospital Necker-Enfants Malades, Neurologie Pediatrique

    Paris, France · Not yet recruiting

  • Sidra Medicine

    Doha, Qatar · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.